KalVista Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2025	FY 2024	FY	FY 2023
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Mar '24 Mar 31, 2024	Apr '23 Apr 30, 2023
Revenue	114.48	73.62	-	-	-	-
Revenue Growth	-	-	-	-	-	-
Cost of Revenue	56.02	54.68	71.71	86.17	-	80.28
Gross Profit	58.47	18.94	-71.71	-86.17	-	-80.28
Selling, General & Admin	198.47	185.21	116.29	54.28	-	30.6
Operating Expenses	198.47	185.21	116.29	54.28	-	30.6
Operating Income	-140	-166.27	-188	-140.45	-	-110.87
Interest Expense	-21.99	-19.34	-5.79	-	-	-
Interest & Investment Income	9.5	8.68	6.44	3.9	-	2.23
Currency Exchange Gain (Loss)	-2.66	0.05	2.48	0.14	-	0.09
Other Non Operating Income (Expenses)	13.64	10.99	3.25	8.44	-	15.78
EBT Excluding Unusual Items	-141.52	-165.89	-181.61	-127.97	-	-92.77
Gain (Loss) on Sale of Investments	1.57	1.84	1.56	1.33	-	-0.14
Asset Writedown	-1.79	-1.79	-	-	-	-
Pretax Income	-141.73	-165.84	-180.05	-126.64	-	-92.91
Income Tax Expense	-5.8	-1.55	3.39	-	-	-
Net Income	-135.94	-164.29	-183.44	-126.64	-	-92.91
Net Income to Common	-135.94	-164.29	-183.44	-126.64	-	-92.91
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	54	54	50	37	-	28
Shares Outstanding (Diluted)	54	54	50	37	-	28
Shares Change	36.50%	8.49%	34.98%	-	-	13.96%
EPS (Basic)	-2.51	-3.05	-3.69	-3.44	-	-3.33
EPS (Diluted)	-2.51	-3.05	-3.69	-3.44	-	-3.33
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2025	FY 2024	FY	FY 2023
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Mar '24 Mar 31, 2024	Apr '23 Apr 30, 2023
Free Cash Flow	-91.71	-124.99	-153.34	-89.27	-	-76.46
Free Cash Flow Per Share	-1.69	-2.32	-3.09	-2.43	-	-2.74
Gross Margin	51.07%	25.73%	-	-	-	-
Operating Margin	-122.30%	-225.86%	-	-	-	-
Profit Margin	-118.74%	-223.16%	-	-	-	-
Free Cash Flow Margin	-80.11%	-169.79%	-	-	-	-
EBITDA	-138.45	-164.82	-187.05	-139.63	-	-110.15
EBITDA Margin	-120.93%	-223.88%	-	-	-	-
D&A For EBITDA	1.56	1.45	0.94	0.82	-	0.72
EBIT	-140	-166.27	-188	-140.45	-	-110.87
EBIT Margin	-122.30%	-225.86%	-	-	-	-

SEC Filings: 10-K · 10-Q